MedTrace Logo

Autologous Immune Enhancement Therapy (AIET) for Cancer Patients

NCT05520372 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-08-29

No results posted yet for this study

Summary

This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021

Conditions

  • Patients With Cancer

Interventions

COMBINATION_PRODUCT

Autologous immune enhancement therapy (AIET) for cancer patients

Autologous NK cell and CD8 T cell therapy for cancer patients

Sponsors & Collaborators

  • Vinmec Research Institute of Stem Cell and Gene Technology

    lead OTHER

Principal Investigators

  • Liem Nguyen Thanh, PhD · Vinmec Research Institute of Stem Cell and Gene Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2021-12-30
Completion
2021-12-30

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05520372 on ClinicalTrials.gov